GSK PLC Sponsored ADR $GSK Shares Newly Acquired by Ativo Capital Management LLC

Key Points

• Ativo Capital Management acquired 31,556 GSK shares during the third quarter, valued at approximately $1.52 million. Institutional investors and hedge funds collectively own 15.74% of the company.
• GSK’s latest reported quarter exceeded expectations, with earnings of $1.36 per share on $11.14 billion in revenue; analysts project full-year earnings of $4.78 per share.
• Analyst sentiment remains cautious, with 13 Hold, three Buy and three Sell ratings and an average price target of $55.48, versus the stock’s reported $48.71 price. Specialty medicines and oncology expansion support growth, but vaccine weakness and rising costs remain concerns.

Ativo Capital Management LLC acquired a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 31,556 shares of the pharmaceutical company's stock, valued at approximately $1,520,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Security National Bank of SO Dak purchased a new position in shares of GSK during the second quarter worth about $38,000. Laurel Wealth Advisors LLC purchased a new stake in shares of GSK in the 3rd quarter valued at about $36,000. Trust Co. of Vermont purchased a new stake in shares of GSK in the 2nd quarter valued at about $54,000. Philadelphia Investment Partners LLC acquired a new stake in shares of GSK in the 2nd quarter valued at about $70,000. Finally, Ancora Advisors LLC acquired a new stake in shares of GSK in the 2nd quarter valued at about $71,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Stock Performance

GSK opened at $48.71 on Thursday. GSK PLC Sponsored ADR has a 1-year low of $45.50 and a 1-year high of $61.69. The stock has a market cap of $98.52 billion, a P/E ratio of 15.23, a P/E/G ratio of 2.28 and a beta of 0.33. The stock's 50 day simple moving average is $49.57 and its 200 day simple moving average is $52.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.09. The business had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $0.47 earnings per share. As a group, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.78 EPS for the current fiscal year.

Analysts Set New Price Targets

GSK has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reiterated a "neutral" rating on shares of GSK in a research report on Tuesday, September 29th. Barclays reissued a "sell" rating on shares of GSK in a report on Monday, September 7th. Royal Bank Of Canada started coverage on shares of GSK in a research report on Tuesday, September 8th. They issued a "sector perform" rating for the company. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Citigroup assumed coverage on GSK in a research report on Friday, July 24th. They set a "neutral" rating on the stock. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $55.48.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Third-quarter results exceeded expectations: Adjusted earnings were approximately $1.47 per ADR, above the $1.40 consensus, while revenue rose about 4% year over year to roughly $11.8 billion. GSK maintained its full-year targets. GSK beats third-quarter profit estimates, keeps annual targets
• Positive Sentiment: Specialty medicines remained the growth engine: HIV, oncology and respiratory products delivered strong or double-digit growth, offsetting weaker vaccines and broadly flat general-medicine sales. GSK Sales Get Boost From Specialty Medicines
• Positive Sentiment: Oncology expansion offers longer-term upside: GSK plans to nearly double the number of cancer drugs in trials next year following recent dealmaking. The company also expects another oncology approval, potentially broadening its growth pipeline. GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
• Neutral Sentiment: Hepatitis B launch preparation: GSK is preparing a concentrated U.S. launch for Hibsago, its newly approved hepatitis B vaccine, which could provide a future boost to the vaccine portfolio but will require successful commercial execution. Hibsago prepares for U.S. hepatitis B launch
• Negative Sentiment: Vaccine weakness overshadowed the earnings beat: Declining adult demand led vaccine revenue to miss expectations, raising concerns about the pace of recovery in a historically important business. GSK shares slide after weaker vaccine sales
• Negative Sentiment: Cost and pipeline concerns persist: Mounting costs and questions about the strength of GSK’s future pipeline reduced the market’s enthusiasm for the solid quarter, leaving investors focused on whether specialty-drug growth can sustainably offset vaccine pressure. GSK shares decline as weaker sales and mounting costs concern investors

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.